Bridget Keenan, MD, PhD

Assistant Professor
Cancer Immunotherapy Program
Division of Hematology/Oncology
Department of Medicine
--

I am a physician scientist who works in translational cancer research and medical oncology. My clinical practice is in the Cancer Immunotherapy Clinic, where I work with patients with solid organ cancers who are being treated on early phase immunotherapy trials. I also attend on the Oncology Consult inpatient service. My research interests are in studying the mechanisms of response and resistance to immunotherapy, with a focus on gastrointestinal cancers.

Publications: 

Abstract CT129: A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer.

Cancer research

Bridget P. Keenan, Christopher H. Lieu, Marwan Fakih, Dongqi Chen, Lucy Lu, Eric Rowinsky, Victor Lu, Lei Xiao, Alan P. Venook, Benjamin Schlechter

Creation of a sustainable longitudinal women in Leadership Development (WILD) curriculum focused on graduate medical education trainees.

BMC medical education

McGourty CA, Castillo F, Donzelli G, Keenan BP, Gilbreth M, Santhosh L

A robust ensemble feature selection approach to prioritize genes associated with survival outcome in high-dimensional gene expression data.

Frontiers in Systems Biology

Phi Le, Xingyue Gong, Leah Ung, Hai Yang, Bridget P. Keenan, Li Zhang, Tao He

Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.

The oncologist

Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K

Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer.

Cancer research communications

Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen BK, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko AH, Fong L, Keenan BP

Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.

Clinical Genitourinary Cancer

Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

JAMA oncology

Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.

Journal for immunotherapy of cancer

Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F

Should I stay, or should I go? Factors associated with intent to leave academic oncology.

Journal of Clinical Oncology

Ana I. Velazquez Manana, Bismarck Odei, Narjust Florez, Sankalp Pandya, Valerie M Dandar, Dame Idossa, Bridget P. Keenan, Katherine Van Loon, Fumiko Chino

Structural Sexism and Cancer Care: The Effects on the Patient and Oncologist.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Keenan BP, Barr E, Gleeson E, Greenberg CC, Temkin SM

A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).

Journal of Clinical Oncology

Hewitt Chang, Luchia Andemicael, Moshiur Mekhail Anwar, John Gordan, Jamese Johnson, Bridget P Keenan, Robin Kate Kelley, Andrew H. Ko, Katherine Van Loon, Alan P. Venook, Lawrence Fong, Melody Ju Xu, Mary Uan-Sian Feng

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Journal of Clinical Oncology

Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng

Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.

Journal of Clinical Oncology

Maira Soto, Erin L Filbert, Hai Yang, Li Zhang, Stephanie Starzinski, Alec Starzinski, Alexander Cheung, Tony Li, Frank J. Hsu, Andrew H. Ko, Lawrence Fong, Bridget P Keenan

Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis.

Cell reports

Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L

1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.

Annals of Oncology

A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran

Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology

Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya

Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial.

Journal of Clinical Oncology

Robin Kate Kelley, Paige M. Bracci, Bridget Keenan, Spencer Behr, Faaiz Ibrahim, Marin Pollak, John Gordan, Andrew H. Ko, Katherine Van Loon, Chloe Evelyn Atreya, Pelin Cinar, Alan P. Venook, Lawrence Fong

676 Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer.

Journal for immunotherapy of cancer

Bridget Keenan, Elizabeth McCarthy, Arielle Ilano, Hai Yang, Li Zhang, Kathryn Allaire, Zenghua Fan, Tony Li, David Lee, Yang Sun, Alexander Cheung, Hewitt Chang, Brenna Sheldon, Robin Kelley, Chun Jimmie Ye, Lawrence Fong

Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy.

Anticancer research

Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY

Key challenges for drugs in clinical development for cholangiocarcinoma.

Expert opinion on investigational drugs

Keenan BP, Kelley RKK

Strategies for forming effective women's groups.

The clinical teacher

Santhosh L, Harleman E, Venado A, Farrand E, E Gilbreth M, Keenan BP, Thompson VV, Shah RJ

Abstract 5512: Identification of circulating myeloid cells induced in advanced biliary cancer patients responding to anti-PD1 through combined single cell RNA sequencing and protein expression analysis.

Cancer research

Bridget P. Keenan, Elizabeth E. McCarthy, Arielle Ilano, David S. Lee, Yang Sun, Brenna Sheldon, Alexander Cheung, Chun Jimmie Ye, Robin Kate Kelley, Lawrence Fong

The "Third Shift": A Path Forward to Recognizing and Funding Gender Equity Efforts.

Journal of women's health (2002)

Santhosh L, Keenan BP, Jain S

Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development.

Cancer prevention research (Philadelphia, Pa.)

Chu NJ, Anders RA, Fertig EJ, Cao M, Hopkins AC, Keenan BP, Popovic A, Armstrong TD, Jaffee EM, Zimmerman JW

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.

Cancer

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK

Abstract 4063: Single cell immune profiling of patients with advanced biliary cancers treated with combination checkpoint inhibition and GM-CSF reveals diverse T cell and myeloid cell mechanisms of action.

Cancer research

Bridget P. Keenan, Whitney Tamaki, Eric Liu, Brandon Chen, Alexander Cheung, John D. Gordan, Brenna Sheldon, Li Zhang, Robin K. Kelley, Lawrence Fong

The Complex Problem of Women Trainees in Academic Medicine.

Journal of hospital medicine

Keenan B, Santhosh L, Thompson V, Harleman E

Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).

Journal of Clinical Oncology

Bridget Keenan, Madeline J Griffith, Kelly Bauer, Paige M. Bracci, Spencer Behr, Sarah E Umetsu, John Dozier Gordan, Zoe Ngo, Syma Iqbal, Diana L. Hanna, Alan P. Venook, Anthony B. El-Khoueiry, Lawrence Fong, Robin Kate Kelley

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

True, True, Related? Autoimmune Polyglandular Syndrome Type II.

The American journal of medicine

Keenan BP, Yalamanchi S, Hsu S, Norsworthy K, Brown TT

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Gastroenterology

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM

Tumor immunology: multidisciplinary science driving basic and clinical advances.

Cancer immunology research

Keenan BP, Jaffee EM, Armstrong TD

Abstract 489: Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development.

Cancer research

Bridget Keenan, Yvonne Saenger, Michel Kafrouni, Ashley Leubner, Peter Lauer, Anirban Maitra, Andrew Gunderson, Lisa Coussens, Todd Armstrong, Elizabeth Jaffee

Abstract PR6: Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development.

Cancer research

Bridget Keenan, Yvonne Saenger, Michel Kafrouni, Ashley Leubner, Peter Lauer, Anirban Maitra, Andrew Gunderson, Lisa Coussens, Todd Armstrong, Elizabeth Jaffee

Whole cell vaccines--past progress and future strategies.

Seminars in oncology

Keenan BP, Jaffee EM

Efficient repair of DNA double-strand breaks in malignant cells with structural instability.

Mutation research

Cheng Y, Zhang Z, Keenan B, Roschke AV, Nakahara K, Aplan PD